false 0001958777 0001958777 2025-01-23 2025-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 23, 2025

 

 

 

FibroBiologics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41934   86-3329066

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

455 E. Medical Center Blvd.

Suite 300

Houston, Texas 77598

(Address of principal executive offices and Zip Code)

 

(281) 671-5150

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock, par value $0.00001 per share   FBLG   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 10, 2025, FibroBiologics, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-284077) with the Securities and Exchange Commission (the “Registration Statement”). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the Summary Compensation Table included in the Registration Statement noted that the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Company had not yet determined annual incentive bonuses for its 2024 fiscal year for the Company’s principal executive officer and two other most highly compensated executive officers for fiscal 2024 (the “Named Executive Officers”), and that the Company would provide an updated Summary Compensation Table following such determination.

 

On January 23, 2025, the Compensation Committee and the Board approved fiscal 2024 annual incentive bonuses for the Named Executive Officers. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated Summary Compensation Table, which includes fiscal 2024 annual incentive bonuses and total compensation figures for the Company’s fiscal year ended December 31, 2024. The Compensation Committee and the Board also approved a bonus of $75,000 for Mr. Robert E. Hoffman, the Company’s Interim Chief Financial Officer.

 

2024 Summary Compensation Table

 

The following table represents information regarding the total compensation awarded to, earned by or paid to our named executive officers during the fiscal years ended December 31, 2023 and 2024:

 

Name and Principal Position  Year   Salary ($)   Bonus ($)   Option Awards ($)(2)   Non-Equity Incentive Plan Compensation ($)(3)   All Other Compensation ($)(4)   Total ($) 
Pete O’Heeron   2024    600,000        788,452    390,000    26,747    1,805,199 
Chairperson and CEO   2023    600,000        3,335,400    300,000    50,908    4,286,308 
                                    
Hamid Khoja, Ph.D.   2024    325,000        341,895    150,000    36,751    853,646 
Chief Scientific Officer   2023    325,000        818,100    113,750    50,908    1,307,758 
                                    
Ruben A. Garcia(1)   2024    270,833    15,000    2,283,274    142,188    41,548    2,752,843 
General Counsel                                   

 

(1) No information is provided with respect to fiscal 2023 for Mr. Garcia because Mr. Garcia was not a named executive officer prior to fiscal 2024. Mr. Garcia joined the Company as General Counsel on March 1, 2024.
(2) Amounts in this column reflect the aggregate grant date fair value of stock options granted, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718, rather than the amounts paid to or realized by the named executive officer. The assumptions used to calculate the grant date fair value of the stock options granted on December 27, 2024 are a $2.36 stock and exercise price, time to maturity of 5.5 years, no dividend yield, an annual risk-free rate of interest of 4.45%, and an annual volatility of 108.93%. The assumptions used to calculate the grant date fair value of the stock options granted to Mr. Garcia on March 1, 2024 are a $13.00 stock and exercise price, time to maturity of 7 years, no dividend yield, an annual risk-free rate of interest of 4.20%, and an annual volatility of 97.28%.
(3) The dollar amounts reflect the incentive bonuses earned by the named executive officers for performance in that fiscal year, which were paid in the subsequent fiscal year.
(4) Amounts in the “All Other Compensation” column for 2024 consist of the amounts set forth in the table below. Healthcare benefits include medical, dental and vision.

 

Named Executive Officer (2024) 

401(k)
Plan Matching

Contributions

($)

  

Healthcare
Benefits

($)

  

Relocation Expenses

($)

 
Pete O’Heeron       26,747     
Hamid Khoja, Ph.D.       36,751     
Ruben A. Garcia   15,525    7,617    18,406 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: January 24, 2025 FibroBiologics, Inc.
     
  By: /s/ Pete O’Heeron
  Name: Pete O’Heeron
  Title: Chief Executive Officer

 

 

 

v3.24.4
Cover
Jan. 23, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 23, 2025
Entity File Number 001-41934
Entity Registrant Name FibroBiologics, Inc.
Entity Central Index Key 0001958777
Entity Tax Identification Number 86-3329066
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 455 E. Medical Center Blvd.
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77598
City Area Code (281)
Local Phone Number 671-5150
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.00001 per share
Trading Symbol FBLG
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false

FibroBiologics (NASDAQ:FBLG)
過去 株価チャート
から 1 2025 まで 2 2025 FibroBiologicsのチャートをもっと見るにはこちらをクリック
FibroBiologics (NASDAQ:FBLG)
過去 株価チャート
から 2 2024 まで 2 2025 FibroBiologicsのチャートをもっと見るにはこちらをクリック